L-055-2023

Agreement ID
L-055-2023
Lead IC
NCI
Exclusivity
Nonexclusive
External Party
Eureka Therapeutics, Inc.
Fiscal Year
2023
Territory
Worldwide
Execution Date
Effective Date
Export Date
Technologies
TAB-4371     Monoclonal Antibodies and Immunoconjugates Directed to the Non-ShedPortion (“Stalk”) of Mesothelin are Excellent Candidates for Developing Therapeutic Agents
TAB-4322     Chimeric Antigen Receptors (CAR)-T Cells that Target the Non-Shed Portion of Mesothelin as a Therapeutic Agent